New York State Common Retirement Fund Boosts Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

New York State Common Retirement Fund increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 190.6% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 137,440 shares of the company's stock after purchasing an additional 90,145 shares during the period. New York State Common Retirement Fund owned approximately 0.11% of Vaxcyte worth $5,190,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Bridgefront Capital LLC boosted its position in Vaxcyte by 4.2% during the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock valued at $347,000 after acquiring an additional 172 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Vaxcyte by 10.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after acquiring an additional 293 shares in the last quarter. Avior Wealth Management LLC boosted its position in Vaxcyte by 5.3% during the 1st quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock valued at $257,000 after acquiring an additional 343 shares in the last quarter. Xponance Inc. lifted its position in Vaxcyte by 4.7% during the 1st quarter. Xponance Inc. now owns 9,320 shares of the company's stock valued at $352,000 after acquiring an additional 415 shares during the period. Finally, National Bank of Canada FI purchased a new position in Vaxcyte during the 4th quarter valued at about $41,000. Hedge funds and other institutional investors own 96.78% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Bank of America lowered their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. The Goldman Sachs Group decreased their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Stock Up 0.2%

NASDAQ PCVX traded up $0.08 on Tuesday, reaching $35.72. The company had a trading volume of 799,893 shares, compared to its average volume of 1,493,061. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The stock has a market cap of $4.61 billion, a price-to-earnings ratio of -8.95 and a beta of 1.19. The stock's 50 day moving average is $33.84 and its 200-day moving average is $53.44.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the business earned ($0.85) earnings per share. As a group, analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.